| Name | Title | Contact Details |
|---|
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, with our research facilities in Hamilton, Ontario.
Dyne was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.
Antibody Solutions is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rapid, Personalized T-cell Therapies for Cancer on BlueSphere Bio…
Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.